March 16 (SeeNews) - Slovenian pharmaceuticals producer Krka [LJE:KRKG] recorded a consolidated net profit of 363.6 million euro ($386.1 million) in 2022, up 18% on an annual basis, it said on Wednesday.
Consolidated sales revenue increased by an annual 10% to 1.717 billion euro in 2022, Krka said in a statement on the group's preliminary operating results for 2022.
The operating profit (EBIT) of the Krka group grew 7% on the year to 381.2 million euro, while the operating profit before depreciation and amortisation (EBITDA) went up 5% to 488.9 million euro.
The group employed 11,598 workers at the end of December, Krka said.
Eastern Europe generated the highest sales within the group - of 623.4 million euro, up 14%, with product sales in Russia - Krka's largest individual market, rising 16%, to 387 million euro.
Sales in Central Europe rose 14% to 364.2 million euro in 2022, followed by sales of 327.3 million euro in Western Europe, up by 7%.
Sales in Southeast Europe grew 7% to 224.5 million euro in the period under review, whereas sales in Slovenia increased 11% to 103.0 million euro and sales in the Overseas Markets segment went up 23% to 66.1 million euro.
($ = 0.9419 euro)
KRKA d.d. is among the biggest companies in SEE. You can download our SEE Top 100 ranking
here or subscribe to our free Top 100 newsletter
here